MORGAN CAULFIELD: Open Payments
NPI 1174087209 · VICKSBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$682 in 38 payments from 11 companies in 2025. Trend: 2023 $375 · 2024 $712 · 2025 $682
Food & beverage: $682
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $207 |
| AstraZeneca Pharmaceuticals LP | 7 | $162 |
| Astellas Pharma US Inc | 4 | $102 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| ABIOMED | 1 | $31 |
| Lilly USA, LLC | 2 | $29 |
| Novo Nordisk Inc | 2 | $29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $15 |
Products named: BREZTRI, Veozah, VRAYLAR, REXULTI, UBRELVY, MOUNJARO, Wegovy, TEFLARO.
Industry payments across MS — which companies pay providers there.
